Nuclear medical imaging as part of dementia diagnostics in psychiatric day-care clinics and inpatient care settings.
Alzheimer’s disease
Amyloid-PET
Dementia
Nuclear medical imaging
Patient care
Journal
Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
04
01
2019
accepted:
24
06
2019
pubmed:
10
7
2019
medline:
18
8
2020
entrez:
10
7
2019
Statut:
ppublish
Résumé
Current guidelines support the use of nuclear medical imaging (NMI) techniques for differential diagnostics of certain cases of dementia. We aimed at studying the association between using NMI and the accuracy of dementia diagnoses. Additionally, we evaluated the effect of conducting NMI on the duration of hospital treatment. This study was based on data collected according to §21 of the German hospital remuneration law, including relevant diagnostic and procedural codes for NMI in dementia patients. In total, more than 7.2 million cases treated in German psychiatric and somatic hospitals between 2015 and 2017 were included. Associations between the frequency of NMI and the accuracy of dementia diagnoses in terms of specific vs. unspecific diagnostic codes were analyzed using Fischer's exact test. In total, 351,106 cases with a dementia diagnosis were encoded during the study period. NMI was performed in 1.03% or 0.15% of all patients with dementia in psychiatric or somatic clinics, respectively. In psychiatric clinics, the proportion of unspecific dementia diagnoses decreased from 20.86% in 2015 to 17.73% in 2017. NMI was mainly performed within psychiatric day-care settings. Interestingly, patients receiving NMI stayed shorter within day-care settings (8.1 ± 16.0 days) compared to inpatient settings (38.3 ± 44.7 days). Nuclear medical imaging is often performed in psychiatric day-care settings. Further studies are warranted to understand the predictive diagnostic value of NMI in dementia diagnosis compared with clinical, CSF and structural imaging in different healthcare settings.
Sections du résumé
BACKGROUND
BACKGROUND
Current guidelines support the use of nuclear medical imaging (NMI) techniques for differential diagnostics of certain cases of dementia.
AIMS
OBJECTIVE
We aimed at studying the association between using NMI and the accuracy of dementia diagnoses. Additionally, we evaluated the effect of conducting NMI on the duration of hospital treatment.
METHODS
METHODS
This study was based on data collected according to §21 of the German hospital remuneration law, including relevant diagnostic and procedural codes for NMI in dementia patients. In total, more than 7.2 million cases treated in German psychiatric and somatic hospitals between 2015 and 2017 were included. Associations between the frequency of NMI and the accuracy of dementia diagnoses in terms of specific vs. unspecific diagnostic codes were analyzed using Fischer's exact test.
RESULTS
RESULTS
In total, 351,106 cases with a dementia diagnosis were encoded during the study period. NMI was performed in 1.03% or 0.15% of all patients with dementia in psychiatric or somatic clinics, respectively. In psychiatric clinics, the proportion of unspecific dementia diagnoses decreased from 20.86% in 2015 to 17.73% in 2017. NMI was mainly performed within psychiatric day-care settings. Interestingly, patients receiving NMI stayed shorter within day-care settings (8.1 ± 16.0 days) compared to inpatient settings (38.3 ± 44.7 days).
CONCLUSIONS
CONCLUSIONS
Nuclear medical imaging is often performed in psychiatric day-care settings. Further studies are warranted to understand the predictive diagnostic value of NMI in dementia diagnosis compared with clinical, CSF and structural imaging in different healthcare settings.
Identifiants
pubmed: 31286431
doi: 10.1007/s40520-019-01257-9
pii: 10.1007/s40520-019-01257-9
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
809-815Références
Clarfield AM (2003) The decreasing prevalence of reversible dementias. Arch Intern Med 163:2219. https://doi.org/10.1001/archinte.163.18.2219
doi: 10.1001/archinte.163.18.2219
pubmed: 14557220
Hejl A, Høgh P, Waldemar G (2002) Potentially reversible conditions in 1000 consecutive memory clinic patients. J Neurol Neurosurg Psychiatry 73:390–394
doi: 10.1136/jnnp.73.4.390
Nobili F, Arbizu J, Bouwman F et al (2018) European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol 25:1201–1217. https://doi.org/10.1111/ene.13728
doi: 10.1111/ene.13728
pubmed: 29932266
Bayer AJ (2018) The role of biomarkers and imaging in the clinical diagnosis of dementia. Age Ageing 47:641–643. https://doi.org/10.1093/ageing/afy004
doi: 10.1093/ageing/afy004
pubmed: 29432519
Boccardi M, Festari C, Altomare D et al (2018) Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. Eur J Nucl Med Mol Imaging 45:1470–1486. https://doi.org/10.1007/s00259-018-4024-1
doi: 10.1007/s00259-018-4024-1
pubmed: 29713763
Knight R, Khondoker M, Magill N et al (2018) A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia. Dement Geriatr Cogn Disord 45:131–151. https://doi.org/10.1159/000486546
doi: 10.1159/000486546
pubmed: 29734182
Tscheuschler M, Gebest M, Jessen F et al (2018) Bedeutung molekularer Bildgebung (PET) in der Diagnostik von Demenzerkrankungen. Nervenarzt 89:843–856. https://doi.org/10.1007/s00115-018-0533-1
doi: 10.1007/s00115-018-0533-1
pubmed: 29916030
Patwardhan MB, McCrory DC, Matchar DB et al (2004) Alzheimer disease: operating characteristics of pet—a meta-analysis. Radiology 231:73–80. https://doi.org/10.1148/radiol.2311021620
doi: 10.1148/radiol.2311021620
pubmed: 15068942
Bloudek LM, Spackman DE, Blankenburg M et al (2011) Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimer’s Dis 26:627–645. https://doi.org/10.3233/JAD-2011-110458
doi: 10.3233/JAD-2011-110458
Foster NL, Heidebrink JL, Clark CM et al (2007) FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease. Brain 130:2616–2635. https://doi.org/10.1093/brain/awm177
doi: 10.1093/brain/awm177
pubmed: 17704526
McKeith I, O’Brien J, Walker Z et al (2007) Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 6:305–313. https://doi.org/10.1016/S1474-4422(07)70057-1
doi: 10.1016/S1474-4422(07)70057-1
pubmed: 17362834
Clark CM, Pontecorvo MJ, Beach TG et al (2012) Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 11:669–678. https://doi.org/10.1016/S1474-4422(12)70142-4
doi: 10.1016/S1474-4422(12)70142-4
pubmed: 22749065
Michalowsky B, Flessa S, Hertel J et al (2017) Cost of diagnosing dementia in a German memory clinic. Alzheimers Res Ther 9:65. https://doi.org/10.1186/s13195-017-0290-6
doi: 10.1186/s13195-017-0290-6
pubmed: 28830516
pmcid: 5568303
Hopf H, Diebels E (2017) Characteristics and practice in german psychiatric day-clinics. Psychiatr Prax 44:228–233. https://doi.org/10.1055/s-0042-115846
doi: 10.1055/s-0042-115846
pubmed: 28125849
Estrella M, Roberts A, Mäurer A et al (2017) Akzeptanz der Demenzdiagnostik bei stationären, geriatrischen Patienten. Z Gerontol Geriatr 50:52–58. https://doi.org/10.1007/s00391-016-1031-3
doi: 10.1007/s00391-016-1031-3
pubmed: 26942458
Deuschl G, Maier W S3-Leitlinie „Demenzen“, http://www.dgn.org/leitlinien , posted 25 Januar 2016, Accessed 29 November 2017. In: Deuschl G, Maier W S3-leitlin. Demenzen. Dtsch. Gesellschaft für Neurol. Hrsg. Leitlinien für Diagnostik und Ther. der Neurol. http://tinyurl.com/hkwk6lf . Accessed 29 Nov 2017
Harper L, Barkhof F, Fox NC et al (2015) Using visual rating to diagnose dementia: a critical evaluation of MRI atrophy scales. J Neurol Neurosurg Psychiatry 86:1225–1233. https://doi.org/10.1136/jnnp-2014-310090
doi: 10.1136/jnnp-2014-310090
pubmed: 25872513
Bermingham SL (2014) The appropriate use of neuroimaging in the diagnostic work-up of dementia: an economic literature review and cost-effectiveness analysis. Ont Health Technol Assess Ser 14:1–67
pubmed: 24592297
pmcid: 3937984
Dormont D, Seidenwurm DJ, Expert Panel on Neurologic Imaging, American College of Radiology (2008) Dementia and movement disorders. AJNR Am J Neuroradiol 29:204–206
pubmed: 18192345
Jack CR, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14:535–562. https://doi.org/10.1016/j.jalz.2018.02.018
doi: 10.1016/j.jalz.2018.02.018
pubmed: 29653606
pmcid: 5958625
Drzezga A (2010) Amyloid-plaque imaging in early and differential diagnosis of dementia. Ann Nucl Med 24:55–66. https://doi.org/10.1007/s12149-009-0330-9
doi: 10.1007/s12149-009-0330-9
pubmed: 20082230
Villemagne VL, Klunk WE, Mathis CA et al (2012) Aβ imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 39:209–219. https://doi.org/10.1007/s00259-011-2045-0
doi: 10.1007/s00259-011-2045-0
pubmed: 22218879
pmcid: 3261395
Kaduszkiewicz H, Wiese B, Steinmann S et al (2013) Diagnosestellung und Diagnosecodierung von Demenzen im Spiegel der Abrechnungsdaten der gesetzlichen Krankenversicherung. Psychiatr Prax 41:319–323. https://doi.org/10.1055/s-0033-1349505
doi: 10.1055/s-0033-1349505
pubmed: 24062153